**Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR)**

Reference Number: CP.PHAR.267  
Effective Date: 01.30.18  
Last Review Date: 05.19  
Line of Business: Medicaid

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Tofacitinib (Xeljanz®, Xeljanz® XR) is a Janus kinase (JAK) inhibitor.

**FDA Approved Indication(s)**

Xeljanz is indicated for the treatment of:
- Adult patients with moderately to severely active ulcerative colitis (UC).

Xeljanz and Xeljanz XR are indicated for the treatment of:
- Adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). They may be used as monotherapy or in combination with MTX or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
- Adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to MTX or other DMARDs.

Limitation(s) of use: Use of Xeljanz/Xeljanz XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

**Policy/Criteria**

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Xeljanz and Xeljanz XR are medically necessary when the following criteria are met:

**I. Initial Approval Criteria**

**A. Rheumatoid Arthritis** (must meet all):

1. Diagnosis of RA;
2. Prescribed by or in consultation with a rheumatologist;
3. Age ≥ 18 years;
4. Member meets one of the following (a or b):
   a. Failure of a ≥ 3 consecutive month trial of MTX at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
   b. If intolerance or contraindication to MTX (see Appendix D), failure of a ≥ 3 consecutive month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated
doses, unless contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed one of the following (a or b):
   a. Xeljanz: 10 mg per day;
   b. Xeljanz XR: 11 mg per day.

**Approval duration: 6 months**

**B. Psoriatic Arthritis** (must meet all):
1. Diagnosis of PsA;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age ≥ 18 years;
4. Dose does not exceed one of the following (a or b):
   a. Xeljanz: 10 mg per day;
   b. Xeljanz XR: 11 mg per day.

**Approval duration: 6 months**

**C. Ulcerative Colitis** (must meet all):
1. Diagnosis of UC;
2. Request is for Xeljanz immediate-release;
3. Prescribed by or in consultation with a gastroenterologist;
4. Age ≥ 18 years;
5. Failure of a ≥ 3 consecutive month trial of azathioprine, 6-mercaptopurine, or aminosalicylate (e.g., sulfasalazine), at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
6. Dose does not exceed 20 mg per day.

**Approval duration: 6 months**

**D. Other diagnoses/indications**
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I** (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
   a. Xeljanz (i or ii):
      i. RA or PsA: 10 mg per day;
      ii. UC: 20 mg per day;
   b. Xeljanz XR: 11 mg per day.

**Approval duration: 12 months**
B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports
      positive response to therapy.
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT
      specifically listed under section III (Diagnoses/Indications for which coverage is
      NOT authorized): CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is
      sufficient documentation of efficacy and safety according to the off label use policies –
      CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   DMARDs: disease-modifying antirheumatic drugs
   FDA: Food and Drug Administration
   JAK: Janus kinase
   MTX: methotrexate
   RA: rheumatoid arthritis
   PsA: psoriatic arthritis
   UC: ulcerative colitis

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval
   criteria. The drugs listed here may not be a formulary agent for all relevant lines of business
   and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>azathioprine (Azasan®, Imuran®)</td>
<td>RA 1 mg/kg/day PO QD or divided BID</td>
<td>2.5 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td>UC 1.5 – 2 mg/kg/day PO</td>
<td></td>
</tr>
<tr>
<td>Cuprimine® (d-penicillamine)</td>
<td>RA* Initial dose:</td>
<td>1,500 mg/day</td>
</tr>
<tr>
<td></td>
<td>125 or 250 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintenance dose:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>500 – 750 mg/day PO QD</td>
<td></td>
</tr>
<tr>
<td>cyclosporine (Sandimmune®, Neoral®)</td>
<td>RA 2.5 – 4 mg/kg/day PO divided BID</td>
<td>4 mg/kg/day</td>
</tr>
<tr>
<td>hydroxychloroquine (Plaquenil®)</td>
<td>RA* Initial dose:</td>
<td>600 mg/day</td>
</tr>
<tr>
<td></td>
<td>400 – 600 mg/day PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintenance dose:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>200 – 400 mg/day PO QD</td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/Maximum Dose</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>leflunomide (Arava®)</td>
<td>RA 100 mg PO QD for 3 days, then 20 mg PO QD</td>
<td>20 mg/day</td>
</tr>
<tr>
<td>6-mercaptopurine (Purixan®)</td>
<td>UC 50 mg PO QD or 1 – 2 mg/kg/day PO</td>
<td>2 mg/kg/day</td>
</tr>
<tr>
<td>mesalamine (e.g., Pentasa®, Asacol®, Lialda®, etc.)</td>
<td>UC Refer to prescribing information</td>
<td>Refer to prescribing information</td>
</tr>
<tr>
<td>methotrexate (Rheumatrex®)</td>
<td>RA 7.5 mg/week PO, SC, or IM or 2.5 mg PO Q12 hr for 3 doses/week</td>
<td>30 mg/week</td>
</tr>
<tr>
<td>Ridaura® (auranofin)</td>
<td>RA 6 mg PO QD or 3 mg PO BID</td>
<td>9 mg/day (3 mg TID)</td>
</tr>
<tr>
<td>sulfasalazine (Azulfidine®)</td>
<td>RA 2 g/day PO in divided doses</td>
<td>RA: 3 g/day</td>
</tr>
</tbody>
</table>
|                                 | UC Initial dose:  
Adults: 3 – 4 g/day PO in divided doses (not to exceed Q8 hrs)  
Pediatrics: 40 – 60 mg/kg/day PO in 3 – 6 divided doses  
Maintenance dose:  
Adults: 2 g PO QD  
Pediatrics: 30 mg/kg/day PO in 4 divided doses | UC: 4 g/day                             |

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Off-label

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): none reported
- Boxed warning(s):
  - There is an increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
  - Lymphoma and other malignancies have been observed.
  - Epstein Barr Virus-associated post-transplant lymphoproliferative disorder has been observed.
Appendix D: General Information

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.

- Examples of positive response to therapy may include, but are not limited to:
  - Reduction in joint pain/swelling/tenderness
  - Improvement in erythrocyte sedimentation rates/C-reactive protein (ESR/CRP) levels
  - Improvements in activities of daily living

- Only the immediate-release version of Xeljanz is FDA-approved for the treatment of UC.
- PsA: According to the 2018 American College of Rheumatology and National Psoriasis Foundation guidelines, TNF inhibitors or oral small molecules (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast) are preferred over other biologics (e.g., interleukin-17 inhibitors or interleukin-12/23 inhibitors) for treatment-naïve disease. TNF inhibitors are also generally recommended over oral small molecules as first-line therapy unless disease is not severe, member prefers oral agents, or TNF inhibitor therapy is contraindicated.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tofacitinib immediate-release</td>
<td>PsA</td>
<td>5 mg PO BID</td>
<td>10 mg/day</td>
</tr>
<tr>
<td>(Xeljanz)</td>
<td>RA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UC</td>
<td>10 mg PO BID for 8</td>
<td>20 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>weeks; then 5 or 10</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mg PO BID</td>
<td></td>
</tr>
<tr>
<td>Tofacitinib extended-release</td>
<td>PsA</td>
<td>11 mg PO QD</td>
<td>11 mg/day</td>
</tr>
<tr>
<td>(Xeljanz XR)</td>
<td>RA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tofacitinib immediate-release</td>
<td>Tablets: 5 mg, 10 mg</td>
</tr>
<tr>
<td>(Xeljanz)</td>
<td></td>
</tr>
<tr>
<td>Tofacitinib extended-release</td>
<td>Tablets: 11 mg</td>
</tr>
<tr>
<td>(Xeljanz XR)</td>
<td></td>
</tr>
</tbody>
</table>

VII. References


**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Medicaid: Policy split from CP.PHAR.86 Rheumatoid &amp; Juvenile Arthritis &amp; Ankylosing Spondylitis Treatments. Policy converted to new template. Removed contraindications of HBV and malignant disease; added dosing requirements; modified criteria to require trial of methotrexate, unless contraindicated; added sulfasalazine as an alternative to MTX if MTX is contraindicated; added requirement for trial and failure of PDL Enbrel and Humira, unless contraindicated; Added the XR formulation to policy. Re-auth: added dosing and reasons to discontinue. Modified approval duration to 6 months for initial and 12 months for renewal; Updated reasons for discontinuation to contraindications and warning and precautions when initiating treatment should be avoided per PI.</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>06.16</td>
<td>07.16</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicaid: Converted to new template. Revised criteria for confirmation of RA diagnosis per 2010 ACR Criteria. Removed safety requirements per updated CPAC Safety Precaution in PA Policies approach.</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.17</td>
<td>07.17</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2Q 2018 annual review: criteria added for new FDA indication: psoriatic arthritis; added HIM; removed TB testing requirement for RA; references reviewed and updated.</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.27.18</td>
<td>05.18</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Criteria added for new indication: ulcerative colitis; allowed bypassing conventional DMARDs for axial PsA and required trial of NSAIDs; references reviewed and updated.</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.17.18</td>
<td>02.19</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2Q 2019 annual review: removed trial and failure requirement of conventional DMARDs (e.g., MTX)/NSAIDs for PsA per 2018 PsA</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.05.19</td>
<td>05.19</td>
<td></td>
</tr>
</tbody>
</table>
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.